PharmExec Blog
Follow Us
RSS
Bookstore
Category Archives: pricing
A Global Consensus: Oncologists Spooked By Health Reforms
In a recent survey by Ipsos Healthcare, oncologists from the US, China, Brazil, and the EU Big 5, expressed strong dissatisfaction with the direction and pace of local healthcare initiatives. Conducted in February of this year, the survey indicates that a substantial portion of its 257 respondents—an average of 40% across these markets – are [...]
Also posted in Global, Market Access, Regulatory Tagged Global, Health Reform, oncologists, Oncology, physicians Leave a comment
Tough Times Ahead for New Medicines under NHS England?
By Leela Barham
You’d be forgiven for missing it with the vast array of new agencies and the policy documents, guidance, consultations and ‘engagement’ activity they’re doing on in the ‘new’ NHS in England, but on the 4th April NHS England (formerly the NHS Commissioning Board) set out 15 commissioning policies in 250 pages. They’re important, [...]
Also posted in Europe, Global, Guest Blog, healthcare Tagged National Health Service, NHS, NICE, R&D, value, value-based pricing Leave a comment
Drug Pipelines in Canada: Is There a Buyer for Future Innovation?
Last week, Canada’s National Prescription Drug Utilization Information System (NPDUIS), a federal-provincial fact-finding panel that works closely with the Patented Medicines Prices Review Board (PMPRB), issued its fourth New Drug Pipeline Monitor (NDPM) looking at drugs currently under development that may have an impact on future drug expenditures. The report is another example of how [...]
Also posted in Global, IP, Market Access, Orphan Drugs, R&D, Regulatory, healthcare Tagged Bernard Lachapelle, Canada, Health Canada, NPDUIS, pipeline, PMPRB Leave a comment
England's Cancer Drug Fund: An Acid Test for Value Based Pricing
By Leela Barham.
England’s Cancer Drugs Fund (CDF) could be in its final financial year, after running in full since April 2011. The fund covers the cost of cancer treatments either when NICE has said ‘no’, or hasn’t yet come to a view. Companies can’t circumvent NICE though; if a company was invited to submit to [...]
Also posted in Europe, Global, Guest Blog, Op-Ed Tagged cancer drug fund, England, NHS, NICE, UK, value-based pricing Leave a comment
Your 2014 Medicaid Sales & Marketing Plans